Sulfuric acid--4-hydroxy-5-({4-[2-({[6-(4-methoxyphenoxy)pyrimidin-4-yl]methyl}amino)ethoxy]phenyl}methyl)-1,3-thiazol-2(5H)-one (1/1)

DescriptionLobeglitazone sulfate, an oral peroxisome proliferator-activated receptor (PPARa/c) dual agonist with IC50 = 20 and 18 nM respectively, was developed by Chong Kun Dang Pharmaceutical in Korea for the treatment of diabetes. This drug is differentiated from two other PPAR agonists available—pioglitazone and rosiglitazone —which lack PPARa activity. The most likely processscale preparation of lobeglitazone sulfate follows the route described in a process communication from Chong Kun Dang Pharmaceutical.

UsesLobeglitazone sulfate is a new type of thiazolidinedione. Lobeglitazone sulfate is the orally active agonist for PPAR with EC50 of 137.4 nM and 546.3 nM for PPARγ and PPARα. Lobeglitazone sulfate is the inhibitor for ERK/JNK/Smad/NF-κB signaling pathway. Lobeglitazone sulfate exhibits anti-inflammatory, anti-diabetic, anti-fibrotic and anti-atherosclerotic properties[1][2][3][4][5][6].